Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
Identifieur interne : 000F97 ( Istex/Curation ); précédent : 000F96; suivant : 000F98Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
Auteurs : Victor S. C. Fung [Australie] ; Lilie Herawati [Australie] ; Ying Wan [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-15.
English descriptors
Abstract
We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. One hundred eighty‐four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ‐8. Secondary outcome measures were the UPDRS parts I–IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ‐8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21878
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F97
Links to Exploration step
ISTEX:175512CAA9FE2609C32FB6996E1F576DBB2267DALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone</title><author><name sortKey="Fung, Victor S C" sort="Fung, Victor S C" uniqKey="Fung V" first="Victor S. C." last="Fung">Victor S. C. Fung</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorder Unit, Department of Neurology, Westmead Hospital, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Movement Disorder Unit, Department of Neurology, Westmead Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Herawati, Lilie" sort="Herawati, Lilie" uniqKey="Herawati L" first="Lilie" last="Herawati">Lilie Herawati</name><affiliation wicri:level="1"><mods:affiliation>Clinical Development and Medical Affairs, Novartis Pharmaceuticals, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Development and Medical Affairs, Novartis Pharmaceuticals</wicri:regionArea></affiliation></author><author><name sortKey="Wan, Ying" sort="Wan, Ying" uniqKey="Wan Y" first="Ying" last="Wan">Ying Wan</name><affiliation wicri:level="1"><mods:affiliation>Development Biostatistic, Novartis Pharmaceuticals, New Jersey, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Development Biostatistic, Novartis Pharmaceuticals, New Jersey</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:175512CAA9FE2609C32FB6996E1F576DBB2267DA</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.21878</idno><idno type="url">https://api.istex.fr/document/175512CAA9FE2609C32FB6996E1F576DBB2267DA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F97</idno><idno type="wicri:Area/Istex/Curation">000F97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone</title><author><name sortKey="Fung, Victor S C" sort="Fung, Victor S C" uniqKey="Fung V" first="Victor S. C." last="Fung">Victor S. C. Fung</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorder Unit, Department of Neurology, Westmead Hospital, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Movement Disorder Unit, Department of Neurology, Westmead Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Herawati, Lilie" sort="Herawati, Lilie" uniqKey="Herawati L" first="Lilie" last="Herawati">Lilie Herawati</name><affiliation wicri:level="1"><mods:affiliation>Clinical Development and Medical Affairs, Novartis Pharmaceuticals, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Development and Medical Affairs, Novartis Pharmaceuticals</wicri:regionArea></affiliation></author><author><name sortKey="Wan, Ying" sort="Wan, Ying" uniqKey="Wan Y" first="Ying" last="Wan">Ying Wan</name><affiliation wicri:level="1"><mods:affiliation>Development Biostatistic, Novartis Pharmaceuticals, New Jersey, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Development Biostatistic, Novartis Pharmaceuticals, New Jersey</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15">2009-01-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="25">25</biblScope><biblScope unit="page" to="31">31</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">175512CAA9FE2609C32FB6996E1F576DBB2267DA</idno><idno type="DOI">10.1002/mds.21878</idno><idno type="ArticleID">MDS21878</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>early Parkinson's disease</term><term>entacapone</term><term>levodopa/carbidopa</term><term>nonfluctuators</term><term>quality of life</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. One hundred eighty‐four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ‐8. Secondary outcome measures were the UPDRS parts I–IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ‐8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. © 2007 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000F97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:175512CAA9FE2609C32FB6996E1F576DBB2267DA
|texte= Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
}}
| This area was generated with Dilib version V0.6.23. |  |